Assoc Prof Weber Lau Kam On

About

Dr Weber Lau graduated with honors from University of Queensland in 1989 and obtained his post-graduate degree in Surgery FRCS in 1994, and FAMS (Urology) from the Academy of Medicine in 2000.

He is currently the Senior Consultant and Director of Uro-oncology, Department of Urology, Singapore General Hospital. 

Dr Weber Lau was promoted to Clinical Senior Lecturer by Faculty of Medicine, National University of Singapore in July 2004 and appointed Adjunct Associate Professor by Duke-NUS Medical School Singapore in Oct 2008.

He was awarded SIU Scholarship in Oncologic and Reconstructive Urology to Urology and Nephrology Center, Mansoura University, Mansoura in Egypt as well as HMDP scholarship in Oncologic Urology to Department of Urology, Mayo Clinic, Rochester in USA in 1999.

He has 60 publications in local and international journals on Prostate Cancers and Bladder Cancers.  He is also actively involved in research and awarded numerous research grants. 

Dr. Lau specializes in genitourinary oncology, urologic surgery and prostate cancer. His areas of clinical and research interest also include Robotic laparoscopic assisted prostatectomy, prostate brachytherapy, prostate specific antigen, PSA, bladder cancer, radical cystectomy, photodynamic diagnosis and therapy and penile cancer.

Education and Training

• MBBS (Aust)
  
• FRCS
  
• FAMS(Urology)
  

Professional Appointments and Committee Memberships

• ​Adjunct Associate Professor, Duke-NUS Medical School
  

Research Interests

• Bladder cancer
• Prostate cancer

Publications

​

• W Lau, C Cheng.  Feasibility of early catheter removal after radical retropubic prostatectomy.  Techniques in Urology 2001; 20(2): 153-158 
  
• W Lau, M Blute, D Bostwick, A Weaver, T Sebo, H Zincke.  Prognostic factors for survival in patients with pathological Gleason 7 prostate: is there a difference in outcome between Gleason 3 +4 versus 4+3.  Journal of Urology 2001; 166: 1692-1697 
  
• H Zincke, W Lau, Erick J Bergstralh, ML Blute.  Role of early adjuvant hormonal therapy after radical prsotatectomy for prostate cancer. Journal of Urology 2001; 166: 2208-2215 
  
• W Lau, M Blute, Erik J Bergstralh, Jeff Slezah, H Zincke.  Radical prostatectomy for Pathological. Gleason >/- 8 prostate cancer – influence of concomitant pathological variables.  Journal of Urology 2002; 167: 117-122 
  
• HG Sim, S Yip, W Lau, YH Tan, M Wong, C Cheng.  Team-based approach reduces learning curve in robot-assisted laparoscopic radical prostatectomy.  IJU 2006; 13: 560-564 
  
• H Ho, YD Chen, PH Tan, M Wang, W Lau, C Cheng.  Inverted papilloma of urinary bladder: is long-term cystoscopic surveillance needed? A single center’s experience.  Urology 2006: 68: 333-336 
  
• W Chin, WS Heng, R Bhuvaneswari, W Lau, M Olivo.  The potential application of chlorine6-polyvinylprrolidone in photodynamic therapy. Photochemistry Photobiology 2006;5: 1031-1037 
  
• Kakoli Das, W Lau, PH Tan, C Cheng.  Differential Expression of VEGF165b in Transitional Cell Carcinoma of Bladder.  Urologic Oncology: Seminars and Original Investigations 2007 
  
• R Mohan, W Lau, C Cheng, T Tan.  Asians with localized prostate cancer treated with 3D-Conformal radiation therapy and adjuvant hormonal therapy: Comparing Phoenix and ASTRO definitions in an Asian population.  Urology 2008; 71: 506-510 
  
• SE Chia, W Lau, CM Chin, J Tan, SH Ho, J Lee, C Cheng.  Effect of ageing and body mass index on prostate-specific antigen levels among Chinese man in Singapore from a community-based study.  BJU 2008; 103: 1487-1491